GlassScriptPhysician profile
Saeyoung Lee
NPI 1316609464
$6,241.39
in general payments reported to CMS, 2019-2025
30 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,410 · 2023: $1,986 · 2024: $1,465 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,682 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,681.85 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $983.19 | 2022-2024 | |
| Ucb, INC. | $728.61 | 2022-2025 | Cimzia, Bimzelx |
| Amgen INC. | $707.97 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Astrazeneca Pharmaceuticals LP | $510.60 | 2022-2025 | Saphnelo |
| Janssen Biotech, INC. | $481.36 | 2022-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $345.00 | 2022-2025 | |
| Pfizer INC. | $280.90 | 2022-2025 | |
| Lilly USA, LLC | $232.50 | 2022-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $230.57 | 2022-2025 | Orencia |
| Glaxosmithkline, LLC. | $206.24 | 2023-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $184.52 | 2022-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $168.03 | 2022-2024 | Strensiq, Ultomiris |
| Janssen Scientific Affairs, LLC | $160.10 | 2022 | |
| Sanofi-Aventis U.S. LLC | $149.98 | 2023-2024 | |
| Kyowa Kirin, INC. | $127.49 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $122.71 | 2022-2025 | Renflexis, Hadlima |
| Genzyme Corporation | $99.22 | 2022-2025 | |
| Radius Health, INC. | $78.06 | 2022-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $73.43 | 2022-2025 | Acthar |
| Kiniksa Pharmaceuticals, LTD. | $65.02 | 2022-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.45 | 2022-2023 | Ofev |
| Sandoz INC. | $47.70 | 2023-2025 | Hyrimoz |
| Sobi, INC | $38.01 | 2022-2024 | |
| Horizon Therapeutics Plc | $33.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.32 | 2025 | Tremfya |
| Lundbeck LLC | $27.05 | 2025 | Rexulti |
| Kiniksa Pharmaceuticals International, Plc | $21.33 | 2024 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $20.40 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.73 | 2025 | Uptravi, Opsumit |
| Octapharma USA, INC. | $15.70 | 2023 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saeyoung Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.